On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of 180 Life Sciences Corp. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 53,935 shares, representing 4.99% of the company's class of securities. This stake is held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The filing also stated that as of the date of the filing, Armistice Capital and Boyd ceased to be the beneficial owners of more than five percent of the class of securities. The Master Fund retains the right to receive dividends or proceeds from the sale of these securities. The filing was completed in accordance with the SEC's rules and regulations, and the information provided was certified as true and correct by Steven Boyd on November 14, 2024.

On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of 180 Life Sciences Corp. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 53,935 shares, representing 4.99% of the company's class of securities. This stake is held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The filing also stated that as of the date of the filing, Armistice Capital and Boyd ceased to be the beneficial owners of more than five percent of the class of securities. The Master Fund retains the right to receive dividends or proceeds from the sale of these securities. The filing was completed in accordance with the SEC's rules and regulations, and the information provided was certified as true and correct by Steven Boyd on November 14, 2024.